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1353JACC Vol. 56, No. 16, 2010 Correspondence
October 12, 2010:1352–6Abnormal Valsalva response results from maintained left ven-
ricular volume owing to excess pulmonary venous capacitance, and
hus should be specific to pathophysiologic states of left-side heart
ongestion. Our results confirm that elevated PVR and right-side
eart congestion only produce an abnormal Valsalva response
hen left-side heart congestion is also present (2). The PAWP was
he only independent predictor of abnormal Valsalva response.
alsalva response did not detect differences in pulmonary artery
ressure; however, patients with a normal response had approxi-
ately one-half the PAWP and nearly double the PVR as the
bnormal group, indicating PH of pulmonary arterial origin. There
ere no episodes of syncope or pre-syncope due to Valsalva,
ncluding among patients with severe PH.
The poor performance of BNP in predicting PAWP is unsur-
rising because our population includes patients with biventricular
athology (3). The E:e=, a Doppler surrogate of left atrial hyper-
ension, performed better but was also disappointing.
This simplified Valsalva method provides valuable hemody-
amic insight during initial PH evaluation. Despite demonstrated
tility in many diseases, the Valsalva maneuver is rarely applied in
ractice (1). We hope this study facilitates the use of this maneuver
s part of the integrated clinical assessment of undifferentiated PH.
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Figure 1 PAWP
Pulmonary artery wedge pressure (PAWP) by Valsalva response (n  84).
Dotted line designates PAWP  15 mm Hg. Bars indicate mean  SD.doi:10.1016/j.jacc.2010.03.095 sEFERENCES
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Letters to the Editor
ronedarone for
trial Fibrillation
ave We Expanded the
ntiarrhythmic Armamentarium?
ecently in the Journal, Singh et al. (1) emphasized the modest
fficacy of dronedarone as a rate and rhythm control agent for atrial
brillation (AF), questioned its safety, and concluded that it is not
n important clinical advance. The rate and rhythm control effects
f dronedarone have been extensively studied and consistently
emonstrated across studies and populations (2–4). Although
ronedarone is less effective against AF recurrence than amioda-
one in persistent AF (5), this was not the point of the ATHENA
A placebo-controlled, double-blind, parallel arm Trial to assess
he efficacy of dronedarone 400 mg bid for the prevention of
ardiovascular Hospitalization or death from any cause in patiENts
ith Atrial fibrillation/atrial flutter) (6). For the first time, a large,
andomized, controlled trial has shown that an antiarrhythmic
herapy can go beyond symptom control by reducing important
ardiovascular outcomes. The ATHENA trial clearly demon-
trated that dronedarone decreases its primary outcome of cardio-
ascular hospitalization or death, with consistent findings across all
mportant subgroups (6). Although the primary outcome was
riven mostly by a reduction in cardiovascular hospitalization,
onetheless, the mortality reduction was consistent with the overall
enefit. Arrhythmic deaths were reduced without evidence that
ther causes of death were increased, and the study also observed
tatistically significant reductions in cardiovascular death and
troke (7). Although these findings need to be confirmed in future
linical studies, these observed reductions in the ATHENA trial
onetheless support the general conclusion that dronedarone
rovides an important clinical benefit in patients with AF (6,7).
educing unplanned hospitalizations for AF and other cardiovas-
ular causes is not a small matter. Not only has cardiovascular
ospitalization been shown to be a strong predictor of subsequent
ortality (8), but also unplanned hospitalizations, usually through
mergency rooms, are widely acknowledged to be serious adverse
vents.
Can we rely on the results of the ATHENA trial, a global,
ulticenter, double-blind, placebo-controlled, randomized clinical
rial? Total mortality was not significantly reduced; however, the
tudy was not powered to demonstrate such a benefit. The
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1354 Correspondence JACC Vol. 56, No. 16, 2010
October 12, 2010:1352–6THENA trial was designed to have only enough deaths to exclude
n important increase in mortality, which it did, with consistent
ndings across all important subgroups (6). In fact, the ATHENA
rial has more clearly demonstrated the safety of dronedarone than has
ver been previously achieved for any other antiarrhythmic drug.
ardiovascular death reduction is a very important finding that not
nly is consistent with the other benefits of dronedarone, but also was
of 3 secondary outcomes pre-specified. Should we discount this
nding because Singh et al. (1) are concerned that increased enroll-
ent from 4,300 to 4,600 patients might have been influenced by
nowledge of emerging trends in treatment effects, even though this
as a double-blind study? The protocol changes made during the
THENA trial were carried out without knowledge of any emerging
reatment effects and were performed to achieve the protocol-specified
oal of having 260 deaths, the required number pre-specified to
xclude an important increase in total mortality. The reduction in
ardiovascular hospitalization is clearly one of the pivotal findings of
he ATHENA trial. Should we, as Singh et al. (1) suggest, discount
his because events were not adjudicated by an external committee?
lthough adjudication would have increased the precision of the out-
ome, it would not have affected the validity of the observation that
ronedarone reduces cardiovascular hospitalization. This is because in-
estigators and patients were blinded to treatment, so there was virtually
o chance for bias. Although we have observed some variation in rates of
ardiovascular hospitalization between regions, the treatment effect of
ronedarone was highly consistent in all regions studied (9).
Should we be concerned that we still do not fully understand the
echanisms whereby dronedarone reduces cardiovascular hospitaliza-
ion and other vascular events? Some mechanisms are obvious—rate
nd rhythm effects slow heart rate and improve a variety of cardio-
ascular conditions, which are adversely affected by high rates. Blood
ressure-lowering and vasodilating and possible ventricular antiar-
hythmic effects may turn out to be important. Future studies will help
s to understand these effects.
The meta-analysis presented by Singh et al. (1) of 6 droneda-
one trials suffers from errors in methodology and accuracy, a few
f which are listed here:
. Inclusion of 1 trial of patients with heart failure (10) together
with 5 trials of patients with AF introduces needless heteroge-
neity, especially because dronedarone is indicated only for AF.
. The binomial approach does not take into account the censor-
ing process, whereas the most widely recommended approach
to summarize time-to-event data in clinical trials is the use of a
hazard ratio.
. The weighting of studies is not explained, nor does it even
reasonably reflect the patient-years of exposure of the studies,
vastly underweighting the ATHENA trial.
. Mean duration of follow-up in the ANDROMEDA (ANti-
arrhythmic trial with DROnedarone in Moderate to severe
congestive heart failure Evaluating morbidity DecreAse) trial is
incorrectly stated. It is 2 months, rather than 13 months (10).
In conclusion, the findings of the ATHENA trial are unique in
ntiarrhythmic drug therapy (6). For the first time, an antiarrhyth-
ic drug has been shown to have an important impact on
ardiovascular outcomes. Physicians no longer need to be satisfied
ith merely suppressing AF symptoms. Let us not miss the forest
or the trees, as Singh et al. (1) seems to have done. The
THENA results really do indicate a promising way forward tomproving patient outcomes through antiarrhythmic therapy. ttuart J. Connolly, MD
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eply
e appreciate the opportunity to clarify the issues raised by Drs.
onnolly and Hohnloser regarding our study (1). We agree that
ronedarone reduces first hospitalizations driven primarily by atrial
brillation in the ATHENA (A placebo-controlled, double-blind,
arallel arm Trial to assess the efficacy of dronedarone 400 mg bid
or the prevention of cardiovascular Hospitalization or death from
ny cause in patiENts with Atrial fibrillation/atrial flutter) trial (2),
ut reject the assertion that this makes it a major advance for the
reatment of atrial fibrillation. Although no other antiarrhythmic
rug has been shown to do this, it is entirely plausible that class I
r III antiarrhythmic drugs would have similar effects if systemat-
cally evaluated in this manner. This is precisely why comparative
ffectiveness research has become a cornerstone of evidence-based
edicine and health care reform. In this regard, it is surprising thathe ATHENA trial was not designed as an active control trial.
